-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – FGF-1 in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FGF-1 in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FGF-1 in Parkinson's Disease Drug Details: FGF-1 is under development for the...
-
Product Insights
Hyperphosphatemia – Drugs In Development, 2023
Global Markets Direct’s, ‘Hyperphosphatemia - Drugs In Development, 2023’, provides an overview of the Hyperphosphatemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hyperphosphatemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Sprifermin in Osteoarthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sprifermin in Osteoarthritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Sprifermin in OsteoarthritisDrug Details:Sprifermin (FGF 18) is under development for the treatment of knee...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Alferminogene Tadenovec in Myocardial Ischemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Alferminogene Tadenovec in Myocardial Ischemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Alferminogene Tadenovec in Myocardial IschemiaDrug Details:Alferminogene tadenovec (Generx) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pixatimod in Metastatic Adenocarcinoma of The Pancreas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pixatimod in Metastatic Adenocarcinoma of The Pancreas report and make more profitable business decisions. How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Roblitinib in Hepatocellular Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Roblitinib in Hepatocellular Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Roblitinib in Hepatocellular Carcinoma Drug Details: Roblitinib (FGF-401) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABSK-061 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABSK-061 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ABSK-061 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABSK-061 in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABSK-061 in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ABSK-061 in Bile Duct Cancer (Cholangiocarcinoma) Drug Details:ABSK-061 is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – FGF-1
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry FGF-1 Drug Details FGF-1 is under development for the treatment of Parkinson's disease, Alzheimer's...